Company Begins Work on Anthrax Vaccine Facility

The U.S. company Emergent BioSolutions Inc. yesterday began developing a new facility capable of producing 100 million doses per year of anthrax vaccine, according to the Associated Press (see GSN, Nov. 16).

The company, which is the parent firm of anthrax vaccine producer BioPort Corp., has purchased a building in Maryland for the $95 million vaccine production plant, which is expected to be completed within two years, AP reported. The U.S. government has agreed to purchase at least 5 million doses of Emergent’s anthrax vaccine.

Emergent’s plant in Lansing, Mich., which has produced more than 5 million anthrax-vaccine doses for U.S. military inoculations, will continue to operate, a company spokeswoman said (David Dishneau, Associated Press/Yahoo!News, Nov. 30).

Back to top
About Newswire  |  Contact National Journal  |  Re-Use Guidelines © Copyright 2008 by National Journal Group, Inc. The material in this section is produced independently for NTI by National Journal Group, Inc. Any reproduction or retransmission, in whole or in part, is a violation of federal law and is strictly prohibited without the consent of the National Journal Group, Inc. All rights reserved.